A new standard of care for elderly patients with myeloma

Lancet

Volumn 370, Issue 9594, 2007, Pages 1191-1192

  Palumbo, Antonio ^a   Boccadoro, Mario ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ENOXAPARIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; GERIATRIC CARE; HUMAN; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; THROMBOEMBOLISM;

EID: 34848851036     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)61522-0     Document Type: Note

References (9)

1. Morgan J., Krishnan B., Jenner M., and Davies F. Advances in oral therapy for multiple myeloma. Lancet Oncol 7 (2006) 316-325
2. Anderson K. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 35 (2007) 155-162
3. Ghobrial I., Leleu X., Hatjiarissi E., et al. Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs 12 (2007) 155-163
4. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6 633 patients from 27 randomized trials. J Clin Oncol 16 (1998) 3832-3842
5. Facon T., Mary J., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370 (2007) 1209-1218
6. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
7. Hulin C., Virion J., Leleu X., et al. Comparison of melphalan-prednisone-thalidomide (MPT) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM): preliminary results of the randomized double-blind, placebo controlled IFM 01-01 trial (Intergroup Francophone du Myelome). J Clin Oncol 25 (2007) 441s (abstr 8001).
8. Ludwig H., Tothova E., Hajek R., et al. Thalidomide-dexamethasone versus melphalan-prednisolone as first line treatment in elderly patients with multiple myeloma: second interim analysis. Hematologica 92 (2007) 166s (abstr 0446).
9. El Accaoui R., Shamsedden W., and Taher A. Thalidomide and thrombosis: a meta-analysis. Thromb Haemost 97 (2007) 1031-1036